Integrin-mediated adhesion is a crucial step in lymphocyte extravasation and homing. We show here that not only the chemokines CXCL12 and CXCL13 but also the lysophospholipids sphingosine 1-phosphate (S1P) and lysophosphatidic acid (LPA) enhance adhesion of murine follicular and marginal zone B cells to ICAM-1 in vitro. This process involves clustering of integrin LFA-1 and is blocked by pertussis toxin, suggesting that G i family G-proteins are involved. In addition, lysophospholipid-induced adhesion on ICAM-1 depends on Rho and Rhokinase, indicative of an involvement of G 12 /G 13 , possibly also G q /G 11 family G-proteins. We used G 12 /G 13 -or G q /G 11 -deficient B cells to study the role of these G-protein families in lysophospholipid-induced adhesion and found that the pro-adhesive effects of LPA and S1P are completely abrogated in G 12 / G 13 -deficient marginal zone B cells, reduced in G 12 /G 13 -deficient follicular B cells, and normal in G q /G 11 -deficient B cells. We also show that loss of lysophospholipid-induced adhesion results in disinhibition of migration in response to the follicular chemokine CXCL13, which might contribute to the abnormal localization of splenic B cell populations observed in B cell-specific G 12 /G 13 -deficient mice in vivo. Taken together, this study shows that lysophospholipids regulate integrin-mediated adhesion of splenic B cells to ICAM-1 through G i and G 12 /G 13 family G-proteins but not through G q /G 11 .
Integrins are adhesion receptors that connect cells to extracellular matrix or to counter-receptors on other cells. Integrinmediated adhesion is critically involved in a variety of processes such as tissue morphogenesis, wound healing, blood clotting, and leukocyte trafficking.
In leukocytes, chemokines and their G-protein coupled receptors (GPCRs) 2 play an important role in the regulation of integrin activity. While a wealth of studies addressed the role of chemokine receptors in lymphocyte homing to lymph nodes and PeyerЈs patches (1, 2) , not much is known about the regulation of B lymphocyte adhesion in the spleen. The spleen contains two subpopulations of mature B cells, follicular B cells and marginal zone B (MZ B) cells, the latter residing at the interface between red and white pulp, the marginal zone. Due to this localization at a site of early antigen contact and due to their high proliferative capacity, MZ B cells play an important role in the rapid defense against blood-borne bacterial antigens (3, 4) . Both entry of follicular B cells into the white pulp (5) and MZ B cell localization within the marginal zone (6) depend on the interaction between lymphocyte integrins LFA (leukocyte function antigen)-1 and ␣ 4 ␤ 1 and their respective ligands on stromal cells, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), respectively. A role for GPCRs in the regulation of this interaction was suggested based on pharmacological or genetic inactivation of different G-protein families in mice. For example, treatment with pertussis toxin (PTX), which ADP-ribosylates and thereby inactivates G i family G-proteins, causes displacement of both follicular B cells and MZ B cells from their physiological niches (5, 7) , suggesting that G i -coupled receptors normally contribute to splenic B cell homing. This hypothesis is strengthened by the finding that numbers of MZ B cells are low in mice lacking either the G␣ i2 subunit of G i (8) or different effector molecules of the G i family like Pyk-2, Rac2, or Dock2 (7, 9, 10) . In addition to G i , also G 12 /G 13 family G-proteins seem to be involved in splenic B cell localization, since MZ B cell numbers are reduced both in B cell-specific G 12 /G 13 -deficient mice (11) and in mice lacking the G 12 /G 13 effector Lsc/p115RhoGEF (12) . However, whether abnormal B cell localization in these mice is due to loss of GPCR-mediated integrin activation or secondary to other defects is not clear.
To elucidate the mechanisms regulating B cell adhesion we studied the effects of chemokine and lysophospholipid GPCR agonists on integrin-mediated adhesion in splenic B cell populations. We show here that not only chemokines, but also the lysophospholipids S1P and LPA, enhance B cell adhesion to ICAM-1, but not to VCAM-1, and that this process involves LFA-1 clustering. We also show that, in contrast to chemokines, lysophospholipids mediate their effects not only through G i family G-proteins but also through the G 12/13 /Rho/Rho-kinase signaling pathway, while G q/11 family G-proteins are not involved.
MATERIALS AND METHODS
Animals-B cell-specific G 12 /G 13 -deficient mice and B cellspecific G q /G 11 -deficient mice were generated by mating the B cell-specific CD19-Cre line (13) 
;Gna12
Ϫ/Ϫ or CD19-Cre ϩ/Ϫ ; Gnaq fl/fl ;Gna11 Ϫ/Ϫ , respectively) mice were generated by intercrosses of triple heterozygous parents.
B cell-specific G␣ q /G␣ 11 -deficient mice were kept on a C57BL6/N background (eighth generation backcross), B cellspecific G␣ 12 /G␣ 13 -deficient mice were kept on a mixed C57BL6/N x Sv129J background, with a predominant contribution of the C57BL6/N strain (fourth generation backcross). Animals were housed under specific pathogen-free conditions. Genotyping was performed as described previously (14, 15) .
Flow Cytometry-Lymphocytes from splenocyte suspension were enriched with Lympholyte-M (Cedarlane, Hornby, Ontario, Canada). B lymphocyte subsets were analyzed with a three-color FACSCalibur flow cytometer and CellQuestPro software (BD Biosciences) using the following antibodies: anti-CD21-FITC, anti-CD23-PE, anti-B220/CD45R-Biotin, anti CD11a-Biotin, anti-CD18-Biotin, rat IgG 2a isotype control, and SA-PerCP (all from BD Biosciences).
Integrin Staining-Untouched B cells were prepared from splenocytes using a B cell isolation kit (Miltenyi, Bergisch-Gladbach, Germany), adhered to ICAM-1-coated coverslips (coated as described for adhesion assays) for 3, 10, or 30 min in the presence or absence of 100 nM S1P or LPA at 37°C/5% CO 2 . Cells were then fixed in ice-cold 4% paraformaldehyde, washed twice in PBS, and incubated with biotinylated anti-CD11a antibody (BD Biosciences, 1:200) for 1 h. After washing in PBS, cells were incubated in SA-TRITC 1:200 in PBS with 2% fetal calf serum (FCS) for 1 h, washed, mounted in Mowiol, and analyzed on a Leica DC300F microscope. To quantify the effect of S1P or LPA on LFA-1 clustering, the number of CD11a clusters per cell was counted at ϫ63 magnification by an investigator blinded to genotype and treatment.
Adhesion Assays-Adhesion assays were performed in 48-well plastic dishes as described (6) with minor modifications. For ICAM-1, wells were coated with 50 g/ml goat-anti-human-IgG-Fc antibody (Jackson ImmunoResearch, West Grove, PA) at 4°C overnight, washed twice with PBS, incubated with 2.5 g/ml mouse ICAM-1-F c (R&D Systems, Minneapolis, MN) in PBS for 2-3 h, and finally blocked with 0.5% BSA/PBS (100 l per well for each step). Uncoated wells were treated with 0.5% BSA/PBS only. For VCAM-1, wells were incubated for 1 h at 37°C with 100 l/well 3 g/ml hVCAM-1 (R&D Systems) in carbonate buffer and blocked with 0.5% BSA/PBS for 30 min before use. In some cases CXCL12 or CXCL13 were co-immobilized together with ICAM-1 or VCAM-1 at a concentration of 0.5 g/ml. Lymphocytes were enriched with Lympholyte-M from splenocyte suspensions and incubated for 30 min in RPMI 1640 medium (Invitrogen, Karlsruhe, Germany) with 10 mM HEPES and 10% heat-inactivated FCS (Invitrogen) at 37°C and 5% CO 2 to remove contaminating macrophages. Non-adherent cells were washed twice, counted, and resuspended at a density of 2 ϫ 10 7 cells/ml in RPMI 1640, 10 mM HEPES, 0.5% FCS. In some cases, cells were pretreated for 1 h at 37°C and 5% CO 2 with 200 ng/ml PTX (Calbiochem/EMD Biosciences), 10 M Y27632 (kind gift from Yoshitomi Pharmaceutical Inc., Osaka, Japan), or 0.2 M TAT-C3 (16) before the adhesion assay. In these cases, the toxins were also present during adhesion. Blocking antibodies directed against CD11a or CD18 or isotype control antibodies (all from BD Biosciences; 1:200) were added only during adhesion.
For the adhesion assay itself, 50 l of cell suspension ( Migration Assays-Lympholyte-M-purified splenocytes were preincubated in RPMI 1640, 10 mM HEPES, 0.1% BSA for 30 min at 37 and 5% CO 2 and then allowed to migrate through uncoated, ICAM-1-coated, or VCAM-1-coated (coating see above) transwell inserts (5 m pore size; Corning, Acton, MA) at a density of 2 ϫ 10 6 splenocytes/100 l/well. The lower wells contained 600 l of RPMI 1640, 10 mM HEPES, 0.1% BSA either without chemokine or with 100 nM CXCL13. If indicated, 100 nM LPA was added to the upper well. After 2 h of incubation at 37 and 5% CO 2 , transwell plates were kept on ice for 20 min and centrifuged at 180 ϫ g for 3 min, inserts were discarded, and cells were stained for B cell subpopulations as described above. Cell numbers were expressed as proportion of input. All experiments were done in triplicates.
Reverse Transcription-PCR-B220 pos , CD21 hi , and CD23 lo marginal zone B cells were sorted with a FACSVantage, and mRNA was prepared with a RNeasy mini kit (Qiagen, Hilden, Germany). Reverse transcription was performed according to standard protocols. LPA receptor subtypes were amplified with the following primers: S1P 1 , 5Ј-GTGTAGACCCAGAGTCCT-GCG-3Ј and 5Ј-AGTACATGGGCCGGTGGAACT-3Ј; S1P 3 , 5Ј-GGAGCCCCTAGACGGGAGT-3Ј and 5Ј-AGCCAAGTT-GCCGATGAAAAAGT-3Ј; S1P 4 , 5Ј-CCTGGAACTCACTTT-ATAGACCAGG-3Ј and 5Ј-CCAGCCTGCCGCTGTGAT-TGTA-3Ј; LPA 1 , 5Ј-GCAGCTGCCTCTACTTCCAC-3Ј and 5Ј-ACGCGCCGGTTGCTCATTC-3Ј; LPA 2 , 5Ј-TGGCGCC-CCAAAGATGTGG-3Ј and 5Ј-TAGCAACCCCAGACCCA-GTG-3Ј; LPA 3 , 5Ј-GCAACACAGACACAGCGGAC-3Ј and 5Ј-CCCACACCAGCAGAATGAGC-3Ј; LPA 4 , 5Ј-AACTGCATT-CCTTACCAACATC-3Ј and 5Ј-GAAAACAAAGAGGCTGA-AATACC-3Ј; LPA 5 , 5Ј-GCAACACAGACACAGCGGAC-3Ј and 5Ј-CCCACACCAGCAGAATGAGC-3Ј.
RhoA Activation Assay-Levels of GTP-bound RhoA were determined in wild-type and mutant splenic B cells before and 1, 3, and 10 min after stimulation with 1 M LPA using a G-LISA RhoA activation kit (Cytoskeleton, Denver, CO).
Extracellular Signal-regulated Kinase (ERK) and Akt Phosphorylation-To determine phosphorylation of ERK and Akt in response to 1 M LPA splenic lymphocytes were incubated at 37°C in the presence or absence of agonist, then fixed for 10 min in 3% paraformaldehyde and permeabilized in 0.1% Triton X-100/PBS for 15 min. To determine ERK phosphorylation in MZ B cells, cells were incubated for 30 min with a FITC-labeled anti-ERK1/2 (pT202/pY204) antibody (BD Biosciences), PerCP-labeled anti-CD45R/B220 antibody, and PE-labeled anti-CD23 antibody, and the mean FITC intensity was determined in CD45R/B220 pos and CD23 neg cells (MZ B cells and newly formed B cells). To determine Akt phosphorylation in MZ B cells, cells were incubated for 30 min with a PE-labeled anti-Akt (pT308) antibody (BD Biosciences), PerCP-labeled anti-CD45R/B220 antibody, and FITC-labeled anti-CD21 antibody, and the mean PE-intensity was determined in CD45R/ B220 pos and CD21 hi cells (MZ B cells). Data are displayed as mean fluorescence intensity as determined by the BD CellQuestPro Software.
Western Blotting-Splenic B cells from control and mutant mice were isolated by magnetic cell sorting (Miltenyi, BergischGladbach, Germany), and membrane bound proteins were extracted as described earlier (17) . Extracts from 10 6 cells per lane were electrophoresed on 10% SDS-PAGE gels and blotted onto nitrocellulose membranes according to standard protocols. Membranes were incubated overnight at 4°C with polyclonal antibodies directed against G␣ 13 (1:1000), G␣ 12 (1:500), G␣ i3 (1:500), and G␣ q/11 (1:500) (all from Santa Cruz Biotechnology, Santa Cruz, CA) or ␣-tubulin antibodies for loading control (Clone DM1a, 1:1000; Sigma). Blots were then incubated with horseradish peroxidase-conjugated secondary antibodies (1:2000; Sigma) for 1 h. Chemiluminescence was developed using the ECLplus kit (Amersham Biosciences, Freiburg, Germany).
Statistics-Data are displayed as mean Ϯ S.E. Comparisons between two groups were performed with Student's t test. Multiple comparisons were performed with analysis of variance and Bonferroni's post hoc test.
RESULTS
To test whether GPCR activation contributes to B cell adhesion in vitro, we incubated murine splenic lymphocytes on ICAM-1-or VCAM-1-coated dishes in the presence or absence of different GPCR agonists and determined the percentage of adherent follicular B or MZ B cells, respectively. We found that the chemokines CXCL12 and CXCL13, as well as the protein kinase C activator phorbol 12-myristate 13-acetate (PMA), strongly enhanced adhesion on ICAM-1-coated plastic in both cell types (Fig. 1, A and B) . On VCAM-1-coated dishes, basal adhesion was generally lower, and although PMA induced a mild but significant increase in adhesion of both MZ B cells and follicular B cell (adherent FoB cells: basal, 4 Ϯ 0.7%; PMA, 10.8 Ϯ 2.8%; adherent MZ B cells: 4.1 Ϯ 0.5%; PMA, 8.5 Ϯ 1.5%; p Ͻ 0.05), CXCL12 and CXCL13 failed to induce significant increases in adhesion (data not shown).
Interestingly, also the lysophospholipids S1P and LPA strongly enhanced adhesion to ICAM-1 in both cell types (Fig.  1, A and B) , while adhesion to VCAM-1 was not affected (data not shown). While effects of CXCL12 and CXCL13 on B cell adhesion have been described before (18) , no direct data exist with respect to lysophospholipid-induced ICAM-1 adhesion. To characterize the pro-adhesive effects of S1P and LPA in more detail, we first tested the involvement of LFA-1, the main interaction partner of ICAM-1 on lymphocytes (19) . We pretreated cells with blocking antibodies directed against LFA-1 ␣-chain CD11a or its ␤-chain CD18 and found that both treatments completely abrogated S1P-or LPA-induced adhesion of MZ B ( Fig. 2A) and follicular B (Fig. 2B ) cells, while pretreatment with isotype control antibodies did not affect adhesion. Two types of integrin activation have been described, enhanced affinity and increased clustering (20 -22), and we found that treatment with 100 nM S1P or LPA significantly enhanced the number of LFA-1 clusters per control cell (Fig. 2C) , while we failed to detect increased binding of soluble ICAM-1 (data not shown). Taken together, these results indicate that lysophospholipids stimulate B cell adhesion to ICAM-1 and that this process involves enhanced LFA-1 clustering.
Since most LPA and S1P receptor subtypes can couple to G i family G-proteins (23, 24) , we investigated the role of G i in lysophospholipid-induced B cell adhesion. Pretreatment of cells with PTX strongly inhibited S1P-or LPA-induced adhesion (Figs. 3, A and B) , suggesting that G i family G-proteins are involved. A potential toxic effect of PTX-treatment on G i -independent pathways in primary B cells can be ruled out, since LPA-induced RhoA activation was not impaired in PTXtreated cells (Fig. 7D) .
Also the small GTPase RhoA has been implicated in GPCRmediated integrin activation (25) , and we tested the effects of the cell permeable version of the RhoA inhibitor Clostridium botulinum exoenzyme C3 (TAT-C3) (16) or the Rho-kinase inhibitor Y27632 (26) . Like PTX these toxins abrogated the pro-adhesive effects of S1P and LPA both in MZ B cells and in follicular B cells (Fig. 3, A and B) , suggesting that also the RhoA/ Rho-kinase cascade critically contributes to agonist-induced adhesion to ICAM.
However, RhoA and Rho-kinase are not typically associated with activation of G i but are rather a main effector pathway of the G 12 /G 13 family of heterotrimeric G-proteins (27) . Since this G-protein family has also been shown to couple to LPA and S1P receptors subtypes (23, 24) , we tested lysophospholipid-induced adhesion in B cells from B cell-specific G 12 /G 13 -deficient mice. Most strikingly, the pro-adhesive effects of S1P and LPA were completely abrogated in G␣ 12 /G␣ 13 -deficient MZ B cells, and reduced in follicular B cells. In contrast, chemokine-induced adhesion was normal (Fig. 4, A and B) . We performed dose response experiments for S1P and LPA and found that while control mice showed a bell-shaped dose-response curve with maximal effects at 100 nM, none of the tested S1P and LPA concentrations enhanced ICAM-1 adhesion in G␣ 12 /G␣ 13 -deficient B cells (Fig. 4, C-F) . In line with this we found that S1P and LPA did not induce significant LFA-1 clustering in mutant cells (Fig. 4G ). Also pretreatment with PTX caused an abrogation of LPA-and S1P-induced LFA-1 clustering (Fig. 4G ). This shows that lysophospholipid receptors mediate their pro-adhesive effects on ICAM-1 not only through G i family G-proteins but also through G 12 /G 13 family G-proteins, and both G-protein families are required for LFA-1 clustering.
To test whether genetic inactivation of G 12 /G 13 leads to altered expression of G i3 or G q /G 11 , we performed Western blotting experiments with wild-type and G␣ 12 /G␣ 13 -deficient B cells. We did not find significant differences in the protein levels of these ␣-subunits between the two genotypes (Fig. 5A) . To rule out that impaired agonist-induced adhesion is due to reduced integrin expression, we analyzed expression of CD11a and CD18 by flow cytometry. We did not find major differences in the distribution of fluorescence intensity between the two genotypes (Fig. 5B) , suggesting that it is indeed integrin activation, and not integrin expression, that is impaired in G␣ 12 / G␣ 13 -deficient B cells. To exclude major differences in the expression levels of S1P and LPA receptors between control and mutant B cells we performed reverse transcriptase polymerase chain reactions for the different receptor subtypes (Fig.  5C) . As described by others (28) , MZ B cells and follicular B cells expressed the S1P receptor subtypes S1P 1 , S1P 3 , and S1P 4 , and expression was comparable between control and mutant B cells. In addition, we found that MZ B and follicular B cells expressed the LPA receptor subtypes LPA 2 , LPA 3 , and weakly also LPA 1 (Fig. 5C ). Of the recently described non-Edg family receptors LPA 4 (29) and LPA 5 (30) only LPA 4 was expressed in MZB cells. Also with respect to LPA receptor subtypes we did not find significant differences in expression levels between the genotypes (Fig. 5C) .
In addition to the G 12 /G 13 family of G-proteins, the G q /G 11 family has been suggested to activate RhoA and Rho-kinase (31) (32) (33) . We therefore investigated whether lysophopsholipid-induced adhesion to ICAM-1 was impaired in B cells from B cell-specific G␣ q /G␣ 11 -deficient mice but did not find significant differences between the genotypes (Fig. 6, A and B) . In these experiments both basal and agonistinduced adhesion to ICAM-1 was lower than in cells from B cell-specific G␣ 12 /G␣ 13 -deficient mice and their respective controls, which is most likely due to differences in the genetic background.
We next investigated which downstream effectors are activated in response to LPA in control, G 12 / G 13 -deficient, or PTX-treated B cells. We found that LPA induced phosphorylation of ERK1/2 and the serine/threonine protein kinase Akt/PKBAkt (Akt) (Fig. 7 , A-C) in wild-type cells. In addition, LPA induced activation of RhoA (Fig.  7D ) in wild-type cells. Both ERK and Akt phosphorylation were completely abrogated in PTX-pretreated cells, while in G 12 /G 13 -deficient B cells Akt phosphorylation was normal and ERK phosphorylation only slightly reduced (Fig. 7,  A-C) . In contrast, PTX treatment did not affect the LPA-induced increase in active, GTP-bound RhoA, while LPA-induced RhoA activation was completely abrogated in G 12 /G 13 -deficient B cells (Fig. 7D) .
B cell-specific G␣ 12 /G␣ 13 -deficient mice show strongly reduced numbers of marginal zone B cells (11) , and we asked whether impaired agonist-induced adhesion to ICAM-1 might contribute to this phenotype. It has been suggested that integrin-mediated adhesion within the marginal zone contributes to MZ B cell homing by counteracting promigratory signals like CXCL13 from adjacent follicles (6) . We therefore tested whether lysophospholipid-mediated enhancement of adhesion impairs migration toward CXCL13 in vitro. Since S1P exerts strong promigratory effects itself (28) and was also shown to facilitate chemokine-induced migration in splenic lymphocytes (34), we used LPA in these experiments. We found that addition of LPA to the upper transwell chamber indeed resulted in a significant reduction of both basal (Fig. 8A, left) and CXCL13-induced (Fig. 8B, left) migration through ICAM-1-coated inserts in control cells. G␣ 12 /G␣ 13 -deficient cells did not differ from control cells with respect to basal or CXCL13-induced migration; however, the anti-migratory effect of LPA was strongly reduced in mutant cells (Fig. 8, A and B, right) . This indicates that the lysophospholipid-induced inhibition of CXCL13-dependent B cell chemotaxis depends on the G 12 /G 13 -mediated signaling pathway. Inhibition of migration was not present on uncoated transwell inserts (Fig. 8, C and D) or VCAM-1 coated inserts (data not shown), suggesting that ICAM-1-mediated adhesion is underlying this effect.
Taken together, these results show that not only chemokines, but also lysophospholipids, can enhance B cell adhesion to ICAM-1 in vitro. The pro-adhesive effects of lysophospholipids are mediated both through G i family G-proteins and the G 12 / G 13 /RhoA/Rho-kinase pathway, but do not involve G q /G 11 family G-proteins. Loss of lysophospholipid-induced adhesion causes disinhibition of migration in response to the follicular chemokine CXCL13, which might contribute to the abnormal localization of splenic B cell populations in B cell-specific G 12 / G 13 -deficient mice.
DISCUSSION
The molecular mechanisms governing integrin-mediated adhesion of splenic B cells are not well understood. We show here that not only chemokines, but also lysophospholipids enhance adhesion of murine B cells to ICAM-1 in vitro, and that this process involves LFA-1 clustering. Integrin activation by non-chemokine GPCRs has been reported in a variety of cellular systems, e.g. for thrombin and thromboxane A 2 receptors in platelets (35) (36) (37) , or for S1P in human and murine cell lines (38, 39) . Indirect evidence for a role of S1P in integrin-mediated processes comes from genetic or pharmacological inactivation of the S1P 1 receptor, which causes impaired lymphocyte entry into secondary lymphoid organs (40) and dislocation of MZ B cells from the marginal zone (28, 41) .
We also show that lysophospholipid-induced adhesion depends on both G i and G 12 /G 13 family G-proteins, while chemokine-induced adhesion does not require G 12 /G 13 . This finding is in line with the general assumption that chemokine GPCRs signal primarily through G i family G-proteins (42) , while lysophospholipid receptors can utilize a variety of different G-protein families (23) . It is not completely clear why activation of G i through chemokine receptors is sufficient to enhance adhesion to ICAM-1, while activation of lysophospho- lipid receptors requires both G i and G 12 /G 13 to do so. Possible explanations might be differences in the expression levels of chemokine versus lysophospholipid receptors or differences in the signaling efficiency of the respective receptors.
MZ B cells and follicular B cells express the S1P receptor subtypes S1P 1 , S1P 3 , and S1P 4 (28) and according to our results also LPA 1 , LPA 2 , and LPA 3 . While S1P 1 and LPA 3 are believed to activate predominantly G i family G-proteins, LPA 1 , LPA 2 , S1P 3 , and S1P 4 were shown to couple to both G i and G 12 /G 13 (24, 43, 44) . Our results show that the pro-adhesive effects of lysophospholipids are mediated both through G 12 /G 13 and G itype G-proteins. Such co-operativity between different G-protein families has been described in other systems, e.g. in platelets, where activation of G i -mediated signaling alone is unable to trigger full activation of integrin ␣IIb␤3 but requires coactivation of G i and G 12 /G 13 family G-proteins (45) (46) (47) .
In addition to the role of G-proteins, we were able to show that lysophospholipid-induced integrin activation involves the small GTPase RhoA and its effector Rho-kinase. This is consistent with a variety of studies showing an involvement of RhoA in integrin-mediated adhesion (25, 48 -50) . Although G 12 /G 13 are believed to be the major mediators of RhoA activation in response to GPCR stimulation, it has been shown that also G q /G 11 family G-proteins can activate RhoA (31, 32) . We did not find differences with respect to lysophospholipid-induced adhesion between control and G␣ q /G␣ 11 -deficient B cells, while LPA-induced RhoA activation is completely abrogated in G 12 /G 13 -deficient B cells. Both findings strongly suggest that G q /G 11 -mediated Rho activation is not critical in this setting, which is in line with the finding that ligand-induced RhoA activation through G q /G 11 occurs with lower potency than G 12 / G 13 -mediated Rho activation (33) . We were able to show that LPA induces not only RhoA activation but also phosphorylation of ERK and Akt in MZ B cells and that the latter effect is predominantly mediated by G i . Although our data do not prove that ERK-and Akt-phosphorylation are critically involved in the proadhesive effects of LPA, our findings suggest that in addition to the G 12/13 /RhoA/ROCK signaling cascade also G imediated ERK and Akt phosphorylation are required for LPAinduced pro-adhesive effects in MZ B cells.
B cell-specific G␣ 12 /G␣ 13 -deficient mice show strongly reduced numbers of splenic MZ B cells but not of follicular B cells (11) . This selective loss of MZ B cells has been attributed to a strong enhancement of migration in these cells (11) , but it seems likely that also impaired lysophospholipid-induced adhesion to ICAM-1 contributes to the phenotype. Lysophospholipids are highly abundant in the blood (51, 52) and therefore seem well suited to mediate localization of lymphocytes to specialized anatomical sites with low blood flow and high ICAM-1 expression such as the marginal zone (6) .
Taken together, this study shows that lysophospholipids regulate LFA-1-dependent adhesion of B cells to ICAM-1 and that this effect depends both on G i and the G 12/13 /Rho/Rho-kinase signaling pathway. Loss of GPCR-mediated pro-adhesive effects might contribute to low MZ B cell numbers observed in mouse models with genetic or pharmacological inactivation of G i (5, 7, 8) or G 12 /G 13 (11) .
